Baker Bros. Advisors (GP) LLC
CIK 1580575 · last filed 2026-10-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SGEN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3RD FLOOR
NEW YORK, NY 10014
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INCY | Director | 3,116,593 | $115.83 | $361.01M | $1.13B | 13 | 2026-10-02 |
| KOD | Director | 19,962,778 | $92.28 | $1.84B | $782.40M | 7 | 2026-09-30 |
| KYMR | Director | — | $117.85 | — | $0 | 2 | 2026-06-25 |
| DNLI | Director | 3,422,366 | $19.27 | $65.95M | $0 | 1 | 2026-06-05 |
| TRDA | 10%+ Owner | 4,541,670 | $4.66 | $21.16M | $6.54M | 2 | 2025-11-12 |
| CELC | 10%+ Owner | 7,211,484 | $67.49 | $486.70M | $38.29M | 1 | 2025-09-10 |
| KNSA | Director | 138,912 | $87.10 | $12.10M | $0 | 2 | 2024-06-07 |
| MDGL | Director | 1,668,553 | $439.38 | $733.12M | $284.55M | 4 | 2023-12-14 |
| IGM Biosciences, Inc. (IGMS) Delisted | Director | 274,006 | $1.27 | $348.0K | $0 | 2 | 2023-07-05 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 93,414 | $184.71 | $17.25M | $0 | 1 | 2023-06-20 |
| PRLD | Director | 876,061 | $3.78 | $3.31M | $0 | 2 | 2023-05-24 |
| TCRX | Director | 253,327 | $0.19 | $48.7K | $15.35M | 1 | 2022-05-12 |
| Seagen Inc. (SGEN) Delisted | Director | 4,103,889 | $228.74 | $938.72M | -$2.33B | 10 | 2021-12-02 |
| ACAD | Director | 3,566,625 | $20.15 | $71.87M | $201.91M | 1 | 2020-03-18 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 1,333,275 | — | — | -$256.29M | 8 | 2019-04-03 |
| Invitae Corp (NVTA) Delisted | 10%+ Owner | 845,858 | $0.09 | $75.4K | $20.00M | 1 | 2018-03-29 |
| RYTM | 1,081,051 | $92.14 | $99.61M | $60.18M | 1 | 2017-10-06 | |
| Aceragen, Inc. (IDRA) Delisted | Director | 7,485 | $7.22 | $54.1K | $0 | 3 | 2017-06-08 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | 10%+ Owner | 30,140 | $58.70 | $1.77M | $40.39M | 3 | 2016-06-09 |
| Neurogene Inc. (AQXP) Delisted | 10%+ Owner | 6,376,467 | — | — | $160.86M | 2 | 2016-01-20 |
Recent Filings · Page 7 of 7
68 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-02-26 | Seagen Inc. (SGEN) Delisted | Buy (P) | +1,887,048 | $55.76M | EDGAR |
| 2016-02-16 | INCY | Buy (P) | +6,210,155 | $433.89M | EDGAR |
| 2016-01-20 | Neurogene Inc. (AQXP) Delisted | Buy (P) | +760,316 | $7.09M | EDGAR |
| 2015-09-18 | INCY | Exer (M) | +32,367,482 | $0 | EDGAR |
| 2015-09-16 | Mirati Therapeutics, Inc. (MRTX) Delisted | Mixed | +600,000 | $27.00M | EDGAR |
| 2015-09-11 | Neurogene Inc. (AQXP) Delisted | Buy (P) | +9,920,128 | $153.76M | EDGAR |
| 2015-02-02 | Mirati Therapeutics, Inc. (MRTX) Delisted | Buy (P) | +2,550,000 | $51.00M | EDGAR |
| 2014-12-17 | Seagen Inc. (SGEN) Delisted | Buy (P) | +17,300,268 | $551.15M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.